ANP are exploring the conditions that would allow MS patients to receive higher doses including potentially generating additional data while monitoring the progress of the DMD trial which could provide support for undertaking studies in MS patients at the FDA approved dose ..
$ sales potentialA case study – Sarepta Therapeutics Inc• Prior to the approval of Exondys 51, Sarepta had a market capitalisation ( m / c ) of ~US$60m (July 2012). Following FDA approval of Exondys 51 Sarepta’s m/c peaked at US$3.3Billion (current m/c US$6Billion)• Exondys 51 is the first FDA approved treatment for DMD, however is only useful in13% of boys with the exon 51 mutation, where as inflammation ycontributes to disease progression in all DMD patients• Cost per patient of Exondys 51 is US$300K/year. Sarepta 2017 annual revenue guidance for Exondys 51 US$150 million• Notably, Mr William Goolsbee, ex Chairman of Sarepta, is a non-executive director of ANP and Exondys 51 inventor,Professor Steve Wilton (Murdoch University, Perth) is a member of the ANP scientific
IMO: Itsagas is lifting his call from $1 to $1.60.
Why?
If the Dmd trial is successful then Spms comes into play...
The article above was announced by ANP in their presentation in Hong Kong..
